BRAF検査の市場：市場規模（セグメント別）、シェア、規制、償還、予測（～2033年）

メラノーマは、世界中で最も基本的な悪性腫瘍の第19位を占めており、年齢標準化された頻度は10万人当たり2.8～3.1人と評価されています。国によって発生頻度に大きな差があり、最も発生頻度が高いのはオーストラリア（10万人当たり37人）で、最も発生頻度が低いのは中南アジア（10万人当たり0.2人）です。このようなパターンは、人種による皮膚の表現型の違いに起因するものであり、世界中の日光浴の違いに起因するものです。皮膚黒色腫を引き起こす基本的な環境因子は紫外線です。

大腸がん（CRC）は男性では3番目に多く、女性では2番目に多いがんです。世界保健機関（WHO）によると、2018年には新たに約180万人のCRC発症例が報告されました。肺がんは2番目に多いがんで、2018年にはおよそ200万人の肺がん新規症例が報告されました。喫煙は、すべての年齢層で肺がんに関連する支配的な危険因子であり、世界の肺がん症例の男性の約80％、女性の約45％が喫煙に起因しています。

BRAF遺伝子は、細胞外から細胞核に特定のシグナルを伝達するタンパク質を作る指針を与えます。このタンパク質はRAF/MAPK経路として知られるシグナル伝達経路の一部であり、いくつかの重要な細胞機能を制御しています。特に、RAF/MAPK経路は、細胞の発生と分裂（増殖）、細胞が特定の機能に発達する手順（分化）、細胞の移動（遊走）、細胞の破裂（アポトーシス）を指示します。この経路を介した化学的シグナル伝達は、出生前の典型的な発達の基本となります。

BRAF検査には、BRAF免疫組織化学（IHC）、BRAFサンガーシークエンシング、BRAF核酸増幅検査（NAAT）、BRAFその他の検査（BRAFインサイチュハイブリダイゼーション（ISH）、マスアレイ検査）が含まれます。

当レポートは、世界のBRAF検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているBRAF検査と競合情勢

• 主要な業界動向の洞察
• BRAF検査のセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• BRAF検査市場のSWOT分析
• BRAF検査市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

List of Tables

Not Applicable

List of Figures

Not Applicable

Abstract

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BRAF Tests market for the year 2020 and beyond. Melanoma is accounted for as the nineteenth most basic malignant growth around the world, with assessed age-standardized frequency rates of 2.8-3.1 per 100,000. There is significant variety in frequency between nations, with the highest rates seen in Australia (37 for every 100,000) and the least in South-Central Asia (0.2 per 100,000). This pattern is ascribed to varieties in racial skin phenotype, just as contrasts in sun exposure around the globe. The fundamental environmental factor causing cutaneous melanoma is UV radiation.

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell's nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis). Chemical signaling through this pathway is basic for typical development before birth.

The BRAF tests include BRAF Immunohistochemistry (IHC), BRAF Sanger sequencing, BRAF Nucleic Acid Amplification Tests (NAATs) and BRAF other Tests (BRAF In Situ Hybridization (ISH), Mass Array Tests).

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRAF Tests market.
• Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRAF Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on BRAF Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving BRAF Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable